Immunoblotting of resected primary tumor verified ALK activation, ALKAL2 expression, and phosphorylation of downstream targets: ERK, AKT, and FRS2 (Fig 4A).32-34 RTK array analysis identified several additional activated RTKs in the tumor sample (Fig 4B). The gene discussed is FRS2; the disease is neoplasm.